656 filings
Page 6 of 33
6-K
cq34jjfe1
2 Sep 21
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
6:35am
6-K
ht50wm
1 Sep 21
Preliminary final report
7:22am
6-K
bd45qq3hw
31 Aug 21
Current report (foreign)
6:09am
6-K
leva7c eypd5
27 Aug 21
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
6:08am
6-K
66ha4
5 Aug 21
Immutep Reports Dosing of First Patient For Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003
6:05am
6-K
tqhl33cypz t4io
2 Aug 21
Immutep completes tranche 2 of its previously announced placement
10:01am
6-K
c9bmjf08xs1
21 Jul 21
Not for release to US wire services or distribution in the United States
6:06am
6-K
wmhkzr fwdao10
13 Jul 21
Immutep Quarterly Activities Report & Appendix 4C
8:31pm
6-K
k9m5iahmg
7 Jul 21
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
12:00am
6-K
740fr2yt nd670flw
22 Jun 21
Immutep completes a A$60 million placement to expand its clinical
12:00am
6-K
36mpxk y3pqk69f
22 Jun 21
Current report (foreign)
12:00am
6-K
hujo9i0c9fli2qydt1fb
9 Jun 21
Current report (foreign)
12:00am
6-K
y9z51jl7ywb2 qpvjucw
7 Jun 21
Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021
12:00am
6-K
ck5nqe pf5r26xwukx
7 Jun 21
Immutep Reports Positive Data from its
12:00am
6-K
n9ll85m0zf 2uy
3 Jun 21
Immutep Secures Second European Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, In Combination with a PD-1 Pathway Inhibitor
12:00am
6-K
7clcom7th86 cjum
2 Jun 21
Current report (foreign)
12:00am
6-K
ey2dhhacu57dabeyil
27 May 21
Immutep Granted Chinese Patent for Eftilagimod Alpha
12:00am
6-K
8eo myv7dstkij24azg
21 May 21
Immutep announces publication of TACTI-002 and INSIGHT-004 abstracts
12:00am
6-K
ns5pal e6pseb97vp6va
10 May 21
Immutep Operational Update
12:00am
6-K
z1g8tm35wq9z qebx
30 Apr 21
Immutep To Announce New TACTI-002 and INSIGHT-004 Data
12:00am